Clinical Trials Logo

Pregnancy in Diabetics clinical trials

View clinical trials related to Pregnancy in Diabetics.

Filter by:

NCT ID: NCT06141434 Recruiting - Type 1 Diabetes Clinical Trials

PRenatal and Obstetric Maternal Exposures and ISlet Autoantibodies in Early Life

PROMISE
Start date: December 1, 2022
Phase:
Study type: Observational

This research study is called 'PRenatal and Obstetric Maternal Exposures and ISlet Autoantibodies in Early Life: The PROMISE Study'. The purpose of this study is to find out more about how exposures during pregnancy, such as having an infection, diet and growth may impact later risk of type 1 diabetes (TID) and islet autoimmunity in the child. We are also interested in finding out more about why having a father or sibling with T1D increases risk of autoimmunity in the child more than having a mother with T1D. We are enrolling women who are pregnant and either have T1D or another first degree relative (father or full sibling) of the baby has T1D. The biological father is also invited to enroll in study, as it is important to understand how the father's health and genetics may contribute to the child's risk of developing T1D. The study procedures for the mother, father and baby are explained below. Mother: Pregnant women will be asked to complete a visit once per trimester (3 visits) during pregnancy and one visit up to 12 weeks after delivery. At each visit, mothers will consent to a blood draw, collection of biological samples and the completion of questionnaires. . Mothers who have T1D will also be asked to download any diabetes device data they have, such as continuous glucose monitor or insulin pump data. Father: The (biological) father will be invited to enroll in a single visit. He will consent to a blood draw and completion of questionnaires. Fathers with T1D will also be asked to download any diabetes device data they have, such as continuous glucose monitor or insulin pump data. Baby: The baby will have blood collected at birth to determine the genetic risk for T1D. Families will consent to the completion of questionnaires about growth, health and diet at 6, 12, 18 and 24 months of age and between 5-7 years of age, and to complete blood testing for islet autoantibodies at 24 months and between 5-7 years of age. For those children with a high genetic risk score, we will also collect blood for autoantibody testing at 6, 12, and 18 months of age.

NCT ID: NCT06111157 Not yet recruiting - Clinical trials for Infant of Diabetic Mother

Infants of Diabetic Mothers in Neonatology Unit at Assiut University Children's Hospital

Start date: March 2024
Phase:
Study type: Observational

Determine spectrum of clinical presentations and complications associated with maternal diabetes mellitus in their newborns attending and admitted to Neonatal Intensive Care Unit of Assiut University Children's Hospital.

NCT ID: NCT06099509 Recruiting - Clinical trials for Gestational Diabetes

Self-Administered 2-Hour Oral Glucose Tolerance Test

Start date: November 2, 2023
Phase: N/A
Study type: Interventional

The goal of this randomized controlled trial is to evaluate whether self-administered postpartum diabetes screening tests in patients with gestational diabetes improves screening completion rates. The primary question it aims to answer is: 1. Does a self-administered 75-gram oral glucose tolerance test with virtual follow-up visit increase the rate of postpartum diabetes screening within 12 weeks of delivery?

NCT ID: NCT06074601 Active, not recruiting - Preterm Birth Clinical Trials

MIRACLE of LIFE Study

MoL
Start date: August 1, 2021
Phase:
Study type: Observational

The goal of this observational study is to develop and validate cell-free RNA-based biomarkers for predicting a variety of adverse pregnancy outcomes in a pregnant person population. The main question it aims to answer are: 1. Can cell-free RNA-based biomarkers predict which pregnant people are at greatest risk of developing adverse pregnancy outcomes (e.g., preterm birth, preeclampsia)? 2. What is the performance of such biomarkers when predicting an adverse pregnancy outcome (e.g., sensitivity, specificity, PPV, NPV, TPR)?

NCT ID: NCT06048510 Recruiting - Clinical trials for Gestational Diabetes Mellitus in Pregnancy

New Markers of Glycation to Predict Gestational Diabetes Mellitus and Macrosomia.

GLYCAGEST
Start date: December 18, 2023
Phase: N/A
Study type: Interventional

Gestational diabetes mellitus (GDM) increases the risk of macrosomia and other adverse pregnancy outcomes. Screening strategies are debated: universal vs. selective, and macrosomia may begin before the time of screening, suggesting that glycation markers may have an interest. The objective of this trail is to compare novel markers: skin autofluorescence and glycated albumin, to HbA1c (reference) as predictors of GDM, macrosomia and other adverse outcomes, in pregnant women.

NCT ID: NCT06031987 Recruiting - Clinical trials for Gestational Diabetes Mellitus in Pregnancy

Long-term Effects of Flash Glucose Monitoring System in Patients With Gestational Diabetes

GDMLIBRE
Start date: January 26, 2022
Phase: N/A
Study type: Interventional

The purpose of this study is to report the glycemic control effect and clinical safety and effectiveness of mother and fetus when using a continuous glucose monitoring system (CGM) [Freestyle Libre] for a long period of time compared to self monitoring blood glucose(SMBG) in gestational diabetes patients.

NCT ID: NCT06021691 Recruiting - Clinical trials for Cognitive Impairment

Gestational Diabetes Mother-infant Cohort

Start date: February 1, 2023
Phase:
Study type: Observational

The bi-directional dynamic cohort study is to learn about the effects of prenatal exposure to high blood glucose levels and postnatal nurturing environment factors on delayed language development in children. The study investigated the results of blood glucose screening during pregnancy for the children's mothers, and followed up on the blood glucose management effectiveness of pregnant women with abnormal blood glucose levels before delivery. Participants will be also surveyed the "S-S method for language development assessment, "gsell Scale", and "0-6 year-old family nurturing environment evaluation scale" to evaluate the language development and family nurturing environment.

NCT ID: NCT06005987 Not yet recruiting - Type 2 Diabetes Clinical Trials

Mobile App Logging for Diabetes in Pregnancy

Start date: November 1, 2023
Phase: N/A
Study type: Interventional

To determine the effect of using a mobile app versus paper logs on compliance and percentage in range blood sugars in monitoring blood sugar in pregnant women with diabetes.

NCT ID: NCT06002997 Completed - Clinical trials for Diabetes Mellitus, Type 1

Periodontal Status and Pregnancy or Delivery Complications in Type 1 Diabetes Mellitus Pregnant Women

Start date: May 3, 2012
Phase:
Study type: Observational [Patient Registry]

The results of contemporary studies suggest an association between inflammatory periodontal disease and pregnancy and delivery complications. The aim of this study was to assess the association between periodontal disease, clinical periodontal parameters and pregnancy or delivery complications in type 1 diabetes mellitus and non-diabetic pregnant women.

NCT ID: NCT05979519 Recruiting - Clinical trials for Type 2 Diabetes Mellitus

Fresh Carts for Mom's to Improve Food Security and Glucose Management

Start date: September 26, 2023
Phase: N/A
Study type: Interventional

This study will look at the benefit of decreasing food insecurity and improving glucose control among women who either report gestational diabetes (GDM) at 20-28-weeks or have type 2 diabetes (T2DM) with a confirmed pregnancy. Participants will receive a grocery prescription with delivery through Instacart at the start of the study or after 12 weeks or frozen medically tailored meals delivered from Door Dash. Researchers will compare the grocery prescription program, MTM (medically tailored meals), relative to standard of care to see if the impact on these food as medicine programs can improve glucose control over 12-weeks as compared to standard of care.